
UCSF Cancer Center
I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer.
I am the Program Leader for GU Medical Oncology program and Associate Director for Clinical Research in the UCSF Helen Diller Family Comprehensive Cancer Center.
My research focus is on developing novel therapies and imaging modalities for patients with advanced solid tumor malignancies, with a focus on patients with advanced prostate cancer.
Honors and Awards
Thomas Perkins Distinguished Professor of Cancer Research, 2024
Prostate Cancer Foundation Challenge Award, 2022
UCSF Division of Hematology & Oncology 2020 Marc A. Shuman Mentoring Award, 2021
Department of Defense Prostate Cancer Program Idea Development Award, 2016-2019
Cancer Clinical Investigator Team Leadership Award, National Cancer Institute, 2016-2017
Department of Defense Prostate Cancer Program Physician Research Training Award, 2016
Prostate Cancer Foundation Young Investigator Award, 2015-2017
Alliance Cooperative Group Scholar Award, 2013
ASCO Young Investigator Award, 2012-2013
Pfizer Fellowship in Oncology, 2011-2012
Publications
Pre- or post-chemotherapy: effect on PSMA uptake.
EJNMMI research
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.
Journal of the National Comprehensive Cancer Network : JNCCN
Racial variation in the advanced prostate cancer genome.
Prostate cancer and prostatic diseases
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study.
European journal of nuclear medicine and molecular imaging
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer.
Current oncology reports
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer.
Molecular oncology
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Journal of the American Heart Association
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research
Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
Clinical cancer research : an official journal of the American Association for Cancer Research
PET Imaging Using 89Zr Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention (EPR) in Prostate Cancer.
Molecular cancer therapeutics
Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
JCO precision oncology
Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.
Cancer medicine
An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression.
Cancer research
Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Germline testing for veterans with advanced prostate cancer: concerns about service-connected benefits.
JNCI cancer spectrum
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.
The Journal of clinical investigation
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
Cancer research communications
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression.
Nature cell biology
68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy.
bioRxiv : the preprint server for biology
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.
Advanced healthcare materials
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.
European journal of heart failure
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.
Cancer immunology research
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Prostate cancer and prostatic diseases
Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5.
Theranostics
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Nature communications
Biomarkers and novel PET imaging to detect neuroendocrine prostate cancer.
Clinical advances in hematology & oncology : H&O
Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer.
Clinical genitourinary cancer
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
European urology oncology
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
British journal of cancer
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
The Lancet. Oncology
A case of cetuximab-induced radiation recall skin dermatitis and review of the literature.
Radiation oncology journal
Enrollment Barriers for Molecular Targeted Trials.
JAMA oncology
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
British journal of cancer
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Clinical genitourinary cancer
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
Frontiers in oncology
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.
Clinical genitourinary cancer
Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other Effects.
European urology focus
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Cancer research
Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
JCO oncology practice
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention.
Urologic oncology
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Urologic oncology
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
Cancer research
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
Nature communications
Improving multiparametric MR-transrectal ultrasound guided fusion prostate biopsies with hyperpolarized 13 C pyruvate metabolic imaging: A technical development study.
Magnetic resonance in medicine
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
Clinical cancer research : an official journal of the American Association for Cancer Research
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Cancer research communications
Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study.
JCO clinical cancer informatics
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
Frontiers in oncology
In Vivo Profiling with 18F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions.
Molecular pharmaceutics
The Emerging Role of Next-Generation Imaging in Prostate Cancer.
Current oncology reports
Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer.
JCO oncology practice
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Nature communications
Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer.
European urology
Clinical translation of hyperpolarized 13 C pyruvate and urea MRI for simultaneous metabolic and perfusion imaging.
Magnetic resonance in medicine
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.
NPJ precision oncology
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
JCO precision oncology
Specialized computational methods for denoising, B1 correction, and kinetic modeling in hyperpolarized 13 C MR EPSI studies of liver tumors.
Magnetic resonance in medicine
Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review.
Translational andrology and urology
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Clinical cancer research : an official journal of the American Association for Cancer Research
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Journal for immunotherapy of cancer
Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
JCO precision oncology
Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
Scientific reports
Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.
Annals of oncology : official journal of the European Society for Medical Oncology
Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy.
Proceedings of the National Academy of Sciences of the United States of America
Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era.
JCO oncology practice
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Clinical cancer research : an official journal of the American Association for Cancer Research
Autoantibody Landscape in Patients with Advanced Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (±)-11C-YJH08 PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.
Therapeutic advances in medical oncology
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
The DNA methylation landscape of advanced prostate cancer.
Nature genetics
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
Proceedings of the National Academy of Sciences of the United States of America
Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography.
ACS chemical biology
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
Prostate cancer and prostatic diseases
Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm.
Molecular imaging and biology
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.
Prostate cancer and prostatic diseases
Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.
Urologic oncology
Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study.
Prostate cancer and prostatic diseases
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
European urology
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
Molecular cancer research : MCR
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Prostate cancer and prostatic diseases
Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies.
Journal of magnetic resonance (San Diego, Calif. : 1997)
Reply to A. Dalla Volta et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients.
Magnetic resonance in medicine
Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
Clinical genitourinary cancer
Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients.
NMR in biomedicine
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Spatio-Temporally Constrained Reconstruction for Hyperpolarized Carbon-13 MRI Using Kinetic Models.
IEEE transactions on medical imaging
Development of an Algorithm to Identify Patients with Physician-Documented Insomnia.
Scientific reports
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
European urology oncology
Technique development of 3D dynamic CS-EPSI for hyperpolarized 13 C pyruvate MR molecular imaging of human prostate cancer.
Magnetic resonance in medicine
Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer.
European urology
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Journal of the National Cancer Institute
Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
European urology
Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer.
The Lancet. Oncology
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
Journal for immunotherapy of cancer
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
Breast cancer research : BCR
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research
Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.
European urology
Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.
Oncology (Williston Park, N.Y.)
Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.
Molecular cancer research : MCR
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
Clinical genitourinary cancer
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.
Journal of vascular and interventional radiology : JVIR
Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
Cancer discovery
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
European urology
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.
Molecular imaging
A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer.
Molecular imaging and biology
Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.
European urology focus
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
Future oncology (London, England)
Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure?
European urology
A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
Annals of oncology : official journal of the European Society for Medical Oncology
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research
Somatostatin imaging of neuroendocrine-differentiated prostate cancer.
Clinical nuclear medicine
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With
Clinical genitourinary cancer
Small-cell/neuroendocrine prostate cancer: a growing threat?
Oncology (Williston Park, N.Y.)
Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.
Cancer chemotherapy and pharmacology
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
Journal of the National Comprehensive Cancer Network : JNCCN
Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
Clinical genitourinary cancer
The changing role of imaging in clinical care.
Nature reviews. Urology
Castration-resistant prostate cancer: targeted therapies and individualized treatment.
The oncologist
The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
Clinical genitourinary cancer